IR BioSciences Holdings IncOver The Counter Market:IRBS
- LAST PRICE0.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
IR BioSciences Holdings Inc | 20.0 | 0.0x | --- |
FluoroPharma Medical Inc | 3.4K | 0.0x | --- |
TetraLogic Pharmaceuticals Corp | 2.5K | 0.0x | --- |
Omnimmune Holdings Inc | 940.0 | 0.0x | --- |
FutureWorld Corp | 5.2K | 0.0x | --- |
Oncovista Innovative Therapies Inc | 2.4K | 0.0x | --- |
Company Information
IR BioSciences Holdings, Inc. is a development-stage biotechnology company. The Company, through its wholly owned subsidiary, ImmuneRegen BioSciences, Inc. (ImmuneRegen), is engaged in the research and development of the drug candidate Homspera for use in therapies in pulmonology, immunology and hematology. The Company focuses on the research and development of therapies in the areas of pulmonary fibrosis, influenza infection and radiation-induced Neutropenia. Other areas of research include vaccine adjuvant activity evinced against certain forms of cancer and applications for wound healing and for regenerating or strengthening the human immune system, in part, through stimulating human adult stem cells.
Contact Information
- Headquarters
- 8777 E. Via De Ventura, Suite 280SCOTTSDALE, AZ, United States 85258
- Phone
- 480-922-3926
- Fax
- 302-636-5454
Executives
- President, Chief Executive Officer, Director
- Michael Wilhelm
- Chief Financial Officer
- John Fermanis
- Vice President, Chief Scientific Officer, Director
- Hal Siegel
- Director
- Lance Gordon
- Director
- Robert Hariri
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $20.00 |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 17.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.36 |
Book Value | $-0.43 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
